1. Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India
- Author
-
Jyoti Bajpai, Pradeep Ventrapati, Shalaka Joshi, Tabassum Wadasadawala, Sushmita Rath, Rima Pathak, Ravindra Nandhana, Samarpita Mohanty, Qurratulain Chougle, Mitchelle Engineer, Nissie Abraham, Jaya Ghosh, Nita Nair, Seema Gulia, Palak Popat, Patil A, Tanuja Sheth, Sangeeta Desai, Meenakshi Thakur, Venkatesh Rangrajan, Vani Parmar, R. Sarin, S. Gupta, and R.A. Badwe
- Subjects
Adult ,Quality of life ,medicine.medical_specialty ,Multivariate analysis ,media_common.quotation_subject ,medicine.medical_treatment ,Fertility ,Breast Neoplasms ,Disease ,Outcomes ,Disease-Free Survival ,Internal medicine ,medicine ,Humans ,Chemotherapy ,Fertility preservation ,Pathological ,RC254-282 ,media_common ,business.industry ,Tertiary Healthcare ,Young breast cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,General Medicine ,Neoadjuvant Therapy ,Chemotherapy, Adjuvant ,Surgery ,Original Article ,Female ,Breast reconstruction ,business - Abstract
Background Young (≤40 years) breast cancers (YBC) are uncommon, inadequately represented in trials and have unique concerns and merit studying. Methods The YBC treated with a curative intent between 2015 and 2016 at our institute were analysed. Results There were 1228 patients with a median age of 36 (12–40) years; 38 (3.1%) had Stage I, 455 (37.1%) - II, 692 (56.3%) –III, and remaining 43 (3.5%) Stage IV (oligo-metastatic) disease; 927 (75.5%) were node positive; 422 (34.4%) were Triple negatives (TNBC), 331 (27%) were HER-2 positive. There were 549 (48.2%) breast conservations and 591 (51.8%) mastectomies of which 62 (10.4%) underwent breast reconstruction. 1143 women received chemotherapy, 617 (53.9%) received as neoadjuvant and 142 (23.1%) had pathological complete response; 934 (81.9%) received adjuvant radiotherapy. At the median follow-up of 48 (0–131) months, 5-year overall and disease-free survival was 79.6% (76.8–82.5) and 59.1% (55.8–62.6). For stage I, II, III and IV, the 5-year overall-survival was 100%, 86.7% (82.8–90.6), 77.3% (73.4–81.2), 69.7% (52.5–86.9) and disease-free survival was 94% (85.9–100), 65.9% (60.3–71.5), 55% (50.5–59.5), and 29.6% (14–45.2) respectively. On multivariate analysis, TNBC and HER-2+ subgroups had poorer survival (p = 0.0035). 25 patients had BRCA mutations with a 5-year DFS of 65.1% (95% CI:43.6–86.6). Fertility preservation was administered in 104 (8.5%) patients; seven women conceived and 5 had live births. Significant postmenopausal symptoms were present in 153 (13%) patients. Conclusion More than half of the YBC in India were diagnosed at an advanced stage with aggressive features leading to suboptimal outcomes. Awareness via national registry and early diagnosis is highly warranted. Menopausal symptoms and fertility issues are prevalent and demand special focus., Highlights • Largest data of young breast cancer from India analysing demographics, outcomes and fertility. • Higher proportion of YBC with advanced stage and aggressive features compared to western data. • Inferior survival in HER-2+ not receiving Trastuzumab, need access of life saving drugs to all. • Scope of improvement and collaboration in challenges like fertility, pregnancy and quality of life.
- Published
- 2021